Skip to main content

Advertisement

SpringerLink
Log in

Immediate changes in blood pressure during intravitreal anti-VEGF agents' applications in exudative age-related macular degeneration patients

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To determine the short-term changes in systemic arterial blood pressure (SABP) during intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in patients with exudative age-related macular degeneration (ARMD).

Materials and methods

This study retrospectively reviewed the data of 550 patients with exudative ARMD, who received intravitreal anti-VEGF (bevacizumab or ranibizumab; selected randomly) injections. Patients with hypertension on medication with antihypertensive drugs were assigned to the hypertension group (HTG; n = 278); those with normal blood pressure and not on antihypertensive drugs were assigned to the normotensive group (NTG; n = 272). The SABP levels were measured 30 min before anti-VEGF injection (baseline = B), during anti-VEGF injection (DI), as well as 30th (I30) and 60th (I60) min after anti-VEGF injection.

Results

Both groups had significantly higher systolic blood pressure (SBP) at DI than that of the baseline values (p < 0.001), whereas the diastolic blood pressures (DBP) increased significantly at DI, I30, and I60 compared with baseline (p < 0.001). In NTG, SBP was significantly higher in patients at I30 (p = 0.019), whereas that in HTG was significantly higher at all measurements (p < 0.05) only in patients who received intravitreal bevacizumab injection.

Conclusion

Our study results show that intravitreal anti-VEGF injection is associated with a short-term increase in SABP. To prevent potential systemic complications during anti-VEGF administration, the systemic status of patients with ARMD should be evaluated before the injection and those with a risk of high SABP during injection should be closely monitored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ng EWM, Adamis AP (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40:353–368

    Google Scholar 

  2. Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:1358–1366

    Article  Google Scholar 

  3. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487

    Article  CAS  Google Scholar 

  4. Rich RM, Rosenfeld FJ, Puliofito CA et al (2006) Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 26:495–511

    Article  Google Scholar 

  5. Fogli S, Del Re M, Rofi E et al (2018) Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond) 32:1010–1020

    Article  CAS  Google Scholar 

  6. Demirçelik G (2009) İntravitreal bevacizumab enjeksiyonu ile ilişkili göze ait ve sistemik komplikasyonlar. Ret Vit 17:269–272

    Google Scholar 

  7. Abdel-Qadir H, Ethier JL, Lee DS et al (2017) Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev 53:120–127

    Article  CAS  Google Scholar 

  8. Van der Reis MI, La Heij EC, De Jong-Hesse Y et al (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31:1449–1469

    Article  Google Scholar 

  9. Avery RL, Gordon GM (2016) Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 134:21–29

    Article  Google Scholar 

  10. Laragh JH, Brenner BM (eds) (1995) Hypertension: pathophysiology, diagnosis and management, 2nd edn. Raven Press, New York, pp 1897–1952

    Google Scholar 

  11. Avery RL, Castellarin AA, Steinle NC et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 37:1847–1858

    Article  CAS  Google Scholar 

  12. Carneiro AM, Costa R, Falcão MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25–30

    Article  CAS  Google Scholar 

  13. Berger V, Munk MR, Lersch F et al (2019) Association of intravitreal injections with blood pressure increase: the following excitement and anxiety response under intravitreal injection study. JAMA Ophthalmol 137:87–90

    Article  Google Scholar 

  14. Risimic D, Milenkovic S, Nikolic D et al (2013) Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration. Hellenic J Cardiol 54(6):435–440

    PubMed  Google Scholar 

  15. Rasier R, Artunay O, Yuzbasioglu E et al (2009) The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 23:1714–1718

    Article  CAS  Google Scholar 

  16. Henry TD, Annex BH, McKendall GR et al (2003) The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107:1359–1365

    Article  CAS  Google Scholar 

  17. Sengul A, Rasier R, Ciftci C et al (2017) Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration. Eye (Lond). 31:677–683

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors alone are responsible for the content and writing of the paper.

Funding

The authors declared that this study received no financial support.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Tıbbiye Cad. No: 40 Üsküdar, 34668, Istanbul, Turkey

    Sevcan Balci, Sehnaz Ozcaliskan & Mehmet Serhat Mangan

  2. Department of Ophthalmology, School of Medicine, Marmara University, Istanbul, Turkey

    Ozlem Sahin & Mehmet Orkun Sevik

Authors
  1. Sevcan Balci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozlem Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sehnaz Ozcaliskan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Orkun Sevik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehmet Serhat Mangan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SYB and OS involved in design and conduct of the study; SYB and OS helped in the preparation and review of the study; SYB, SO, MOS, MSM contributed to data collection.

Corresponding author

Correspondence to Sevcan Balci.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balci, S., Sahin, O., Ozcaliskan, S. et al. Immediate changes in blood pressure during intravitreal anti-VEGF agents' applications in exudative age-related macular degeneration patients. Int Ophthalmol 40, 2515–2522 (2020). https://doi.org/10.1007/s10792-020-01431-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-020-01431-3

Keywords

Search

Navigation